{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:42:14Z","timestamp":1777610534092,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.euroneuro.2013.07.011","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T23:16:16Z","timestamp":1376435776000},"page":"448-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: An animal model"],"prefix":"10.1016","volume":"24","author":[{"given":"Margaret K.","family":"Hahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araba","family":"Chintoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Arenovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Nobrega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Guenette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adria","family":"Giacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2013.07.011_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0014-2999(95)00292-S","article-title":"Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine","volume":"283","author":"Arnt","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib2","first-page":"E22","article-title":"Nucleus ambiguus stimulation increases plasma insulin levels in the rat","volume":"241","author":"Bereiter","year":"1981","journal-title":"Am. J. Physiol."},{"issue":"Suppl. 3","key":"10.1016\/j.euroneuro.2013.07.011_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2362.32.s3.5.x","article-title":"The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes","volume":"32","author":"Bergman","year":"2002","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"Boyda","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","article-title":"Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model","volume":"108","author":"Chintoh","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/JCP.0b013e318184b4c5","article-title":"Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration","volume":"28","author":"Chintoh","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib7","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.bcp.2010.01.029","article-title":"The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells","volume":"79","author":"de Leeuw van Weenen","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc11-0064","article-title":"Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes","volume":"34","author":"Defronzo","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2337\/diacare.19.3.278","article-title":"In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance","volume":"19","author":"Elahi","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib10","doi-asserted-by":"crossref","first-page":"e20571","DOI":"10.1371\/journal.pone.0020571","article-title":"Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation","volume":"6","author":"Ferno","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib11","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2337\/diab.36.8.914","article-title":"Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates","volume":"36","author":"Finegood","year":"1987","journal-title":"Diabetes"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0028-3908(74)90075-6","article-title":"Mechanisms of hyperglycemic response to chlorpromazine administered into lateral ventricle in rats. II. Secretion of epinephrine from adrenal medulla","volume":"13","author":"Fujimori","year":"1974","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib13","first-page":"565","article-title":"Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function","volume":"22","author":"Gilon","year":"2001","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","article-title":"Schizophrenia and increased risks of cardiovascular disease","volume":"150","author":"Hennekens","year":"2005","journal-title":"Am. Heart J."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-8993(78)90408-0","article-title":"A mapping of the distribution of acetycholine, choline acetyltransferase and acetylcholinesterase in discrete areas of rat brain","volume":"153","author":"Hoover","year":"1978","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/10401230209147399","article-title":"Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases","volume":"14","author":"Jin","year":"2002","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib18","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib19","doi-asserted-by":"crossref","first-page":"E520","DOI":"10.1152\/ajpendo.2000.279.3.E520","article-title":"Overnight inhibition of insulin secretion restores pulsatility and proinsulin\/insulin ratio in type 2 diabetes","volume":"279","author":"Laedtke","year":"2000","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-0773.1994.tb00351.x","article-title":"Pharmacological comparison of antipsychotic drugs and sigma-antagonists in rodents","volume":"75","author":"Lang","year":"1994","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1210\/endo-117-1-307","article-title":"The hepatic vagus nerve and the neural regulation of insulin secretion","volume":"117","author":"Lee","year":"1985","journal-title":"Endocrinology"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0091-3057(85)90025-5","article-title":"A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs","volume":"23","author":"Ljungberg","year":"1985","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0006-8993(94)90657-2","article-title":"CNS monoamine cell groups projecting to pancreatic vagal motor neurons: a transneuronal labeling study using pseudorabies virus","volume":"638","author":"Loewy","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib24","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2337\/db10-0449","article-title":"Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance","volume":"59","author":"Martins","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1152\/physiol.00010.2007","article-title":"Brain glucose sensing, counterregulation, and energy homeostasis","volume":"22","author":"Marty","year":"2007","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus","volume":"20","author":"Matsui-Sakata","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib27","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2337\/db05-1359","article-title":"Activation of AMP-activated protein kinase within the ventromedial hypothalamus amplifies counterregulatory hormone responses in rats with defective counterregulation","volume":"55","author":"McCrimmon","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib28","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1172\/JCI30440","article-title":"Hypothalamic resistin induces hepatic insulin resistance","volume":"117","author":"Muse","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2013.07.011_bib29","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia","volume":"59","author":"Newcomer","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.07.011_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0165-1838(95)00101-8","article-title":"Intracerebroventricular injection of methylatropine suppresses insulin response to oral glucose load in rats","volume":"57","author":"Ohnuma","year":"1996","journal-title":"J. Auton Nerv. Syst."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00006","article-title":"Medical hazards of obesity","volume":"119","author":"Pi-Sunyer","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/schbul\/sbn104","article-title":"Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation","volume":"36","author":"Savoy","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1358\/mf.2005.27.5.908643","article-title":"Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes","volume":"27","author":"Silvestre","year":"2005","journal-title":"Methods Findings Exp. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib35","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0021-9258(19)77804-1","article-title":"Rates of glucose production and oxidation in normal and diabetic rats","volume":"192","author":"Stetten","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0006-8993(87)90268-X","article-title":"Distribution of choline acetyltransferase-containing neurons of the hypothalamus","volume":"415","author":"Tago","year":"1987","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1210\/jc.2008-1815","article-title":"Effects of olanzapine and haloperidol on the metabolic status of healthy men","volume":"95","author":"Vidarsdottir","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.euroneuro.2013.07.011_bib38","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cmet.2007.10.008","article-title":"Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways","volume":"6","author":"Zhou","year":"2007","journal-title":"Cell Metab."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13002113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13002113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T18:23:20Z","timestamp":1646331800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X13002113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0924977X13002113"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.07.011","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: An animal model","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}